Dr. Thomas Patterson, chief of the Division of Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir.
Dr. Thomas Patterson, chief of the Division of Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir.